Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that management will present a company update at the Jefferies 2018 London Healthcare Conference. The presentation will take place at 5:20 p.m. GMT on Thursday, November 15, 2018.
About Bicycle Therapeutics
Bicycle Therapeutics is
developing a unique class of chemically synthesised medicines based on
its proprietary bicyclic peptide (Bicycle®)
product platform to address therapeutic needs unreachable with existing
treatment modalities. Bicycle’s internal focus is in oncology, where the
company is developing targeted cytotoxics (Bicycle Toxin Conjugates®),
targeted innate immune activators and T-cell modulators for cancers of
high unmet medical need. Bicycles’ small size and
exquisite targeting deliver rapid tumour penetration and retention while
clearance rates and routes of elimination can be tuned to minimise
exposure of healthy tissue and bystander toxicities. The company’s lead
program, BT1718, is being evaluated in a Phase I/IIa trial in
collaboration with Cancer Research UK. The company’s unique intellectual
property is based on the work initiated at the MRC Laboratory of
Molecular Biology in Cambridge, U.K., by the scientific founders of the
company, Sir Gregory Winter, a winner of the Nobel Prize in Chemistry
for his pioneering work in phage display of peptides and antibodies, and
Professor Christian Heinis. Bicycle has its headquarters in Cambridge,
U.K., with many key functions and members of its leadership team located
in the biotech hub of Boston, Mass. For more information, visit www.bicycletherapeutics.com or
follow us on Twitter at @Bicycle_tx.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181108005252/en/
Media:
Ten Bridge Communications (U.S.)
Sarah Sutton,
+1-857-242-1619
Sarah@tenbridgecommunications.com
or
Investors:
Argot
Partners
Maeve Conneighton, +1-212-600-1902
maeve@argotpartners.com